IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
National Cancer Institute · Center for Cancer Research
Abstract
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy…
Citation impact
- FWCI
- 43.35
- Percentile
- 100%
- References
- 136
Authors
8- SHSue HanCorresponding
National Cancer Institute, Center for Cancer Research
- YLYang Liu
National Cancer Institute, Center for Cancer Research
- SJSabrina J. Cai
National Cancer Institute, Center for Cancer Research
- MQMingyu Qian
National Cancer Institute, Center for Cancer Research
- JDJianyi Ding
National Cancer Institute, Center for Cancer Research
Topics & keywords
- Isocitrate dehydrogenase
- Biology
- IDH1
- Carcinogenesis
- Epigenetics
- Cancer research
- Glioma
- IDH2
- Good health and well-being